-base

A1C is a blood test for type 2 diabetes and prediabetes. It measures your average blood glucose, or blood sugar, level over the past 3 months. Doctors may use the A1C alone or in combination with other diabetes tests to make a diagnosis. They also use the A1C to see how well you are managing your diabetes. This test is different from the blood sugar checks that people with diabetes do every day.

Your A1C test result is given in percentages. The higher the percentage, the higher your blood sugar levels have been:

A normal A1C level is below 5.7%
Prediabetes is between 5.7 to 6.4%. Having prediabetes is a risk factor for getting type 2 diabetes. People with prediabetes may need retests every year.
Type 2 diabetes is above 6.5%
If you have diabetes, you should have the A1C test at least twice a year. The A1C goal for many people with diabetes is below 7. It may be different for you. Ask what your goal should be. If your A1C result is too high, you may need to change your diabetes care plan.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

-base FDA Approved Drugs

AKNE-MYCIN [Erythromycin^{C₃₇H₆₇NO₁₃}]

2% (topical ointment)

Dow Pharm^{Jan 10, 1985}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERY-TAB [Erythromycin^{C₃₇H₆₇NO₁₃}]

250mg (oral tablet, delayed release)

333mg (oral tablet, delayed release)

500mg (oral tablet, delayed release)

Arbor Pharms Llc^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERYC [Erythromycin^{C₃₇H₆₇NO₁₃}]

250mg (oral capsule, delayed rel pellets)

Mayne Pharma^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERYGEL [Erythromycin^{C₃₇H₆₇NO₁₃}]

2% (topical gel)

Mylan Pharms Inc^{Oct 21, 1987}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERYTHROMYCIN [Erythromycin^{C₃₇H₆₇NO₁₃}]

0.5% (ophthalmic ointment)

2% (topical swab)

250mg (oral tablet)

500mg (oral tablet)

Akorn^{Jul 18, 1996}
Bausch And Lomb^{Jul 29, 1994}
Perrigo Co Tennessee^{Sep 26, 1983}
Fougera Pharms^{Sep 30, 1997}
Perrigo New York^{Jan 11, 1991}
Wockhardt^{Oct 23, 1987}
Arbor Pharms Llc^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

GILOTRIF [Afatinib Dimaleate^{C₂₄H₂₅ClFN₅O₃2C₄H₄O₄}]

eq 20mg base (oral tablet)

eq 30mg base (oral tablet)

eq 40mg base (oral tablet)

Boehringer Ingelheim^{Jul 12, 2013}

Treatment of cancer.
Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

KISQALI [Ribociclib Succinate^{C₂₃H₃₀N₈OC₄H₆O₄}]

eq 200mg base (oral tablet)

Novartis Pharms Corp^{Mar 13, 2017}

In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

KISQALI FEMARA CO-PACK (COPACKAGED) [Letrozole^{C₁₇H₁₁N₅} : Ribociclib Succinate^{C₂₃H₃₀N₈OC₄H₆O₄}]

2.5mg,n/a : n/a,eq 200mg base (oral tablet, tablet)

Novartis Pharms Corp^{May 4, 2017}

In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LONSURF [Tipiracil Hydrochloride^{C₉H₁₁ClN₄O₂ClH} : Trifluridine^{C₁₀H₁₁F₃N₂O₅}]

eq 6.14mg base : 15mg (oral tablet)

eq 8.19mg base : 20mg (oral tablet)

Taiho Oncology^{Sep 22, 2015}

Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ONIVYDE [Irinotecan Hydrochloride^{C₃₃H₃₈N₄O₆ClH3H₂O}]

eq 43mg base/10ml (eq 4.3mg base/ml) (iv (infusion) injectable, liposomal)

Ipsen Inc^{Oct 22, 2015}

Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele.
Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of pancreatic cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

PCE [Erythromycin^{C₃₇H₆₇NO₁₃}]

333mg (oral tablet, coated particles)

500mg (oral tablet, coated particles)

Arbor Pharms Llc^{Sep 9, 1986}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

PROMACTA [Eltrombopag Olamine^{C₂₅H₂₂N₄O₄2C₂H₇NO}]

eq 100mg acid (oral tablet)

eq 12.5mg acid (oral tablet)

eq 25mg acid (oral tablet)

eq 25mg acid/packet (oral for suspension)

eq 50mg acid (oral tablet)

eq 75mg acid (oral tablet)

Novartis Pharms Corp^{Nov 16, 2012}

Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
Topical treatment of interdigital tinea pedis and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes or epidermophyton floccosum.
Treatment of idiopathic thrombocytopenic purpura (itp).
Treatment of immune (idiopathic) thrombocytopenia (itp).
Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp).
Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

TARCEVA [Erlotinib Hydrochloride^{C₂₂H₂₃N₃O₄ClH}]

eq 100mg base (oral tablet)

eq 150mg base (oral tablet)

eq 25mg base (oral tablet)

Osi Pharms^{Nov 18, 2004}

First-line treatment of locally advanced unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
First-line treatment of metastatic non smal-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test.
Maintenance treatment in patients with locally advanced or metastatic nsclc who have not progressed on 1st-line treatment wth platinum-based chemotherapy.
Maintenance treatment of patients with locally advanced or metastatic nsclc whose disease has not progressed after four cycles platinum-based chemotherapy.
Treatment of locally advanced or metastatic non small-cell lung cancer (nsclc) after failure of at least one prior chemotherapy regimen.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Felter's Materia Medica on -base

PASSIFLORA^PABE10
The root and stem-base of Passiflora incarnata, Linné (Nat. Ord. Passifloraceae). Southern United States. Dose, 5 to 120 grains. Common Names: Passion Flower, May Pop. Principal... / The root and stem-base of Passiflora incarnata, Linné (Nat. Ord. Passifloraceae). Southern United States. Dose, 5 to...¹

References

1) Felter, Harvey Wickes, 1922, The Eclectic Materia Medica, Pharmacology and Therapeutics, Cincinnati, Ohio.

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

-base

-base FDA Approved Drugs

Felter's Materia Medica on -base

References